<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911556</url>
  </required_header>
  <id_info>
    <org_study_id>Z202002</org_study_id>
    <nct_id>NCT04911556</nct_id>
  </id_info>
  <brief_title>the Effect of Probiotics on Aging Population</brief_title>
  <acronym>TEOPOGP</acronym>
  <official_title>Study for the Effect of Probiotics on Aging Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuxi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuxi People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to recruit aging population (over 65 years old). The investigators use 16&#xD;
      SrDNA sequencing technology, genome sequencing technology, metabonomics, random forest&#xD;
      forecast model, analysing and selecting specific age-related intestinal flora. The&#xD;
      investigators select probiotics slowing down senility. Then the investigators use the&#xD;
      probiotics to intervene in the aging population. Finally the investigators observe whether&#xD;
      the probiotics can delay aging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project plans to recruit the aging population (aged over 65 years old) and&#xD;
      comprehensively analyze the public database and self-sequencing clinical big data by using 16&#xD;
      srDNA sequencing technology, metagenomic sequencing technology, metabonomics methods and&#xD;
      Random Forest (R) prediction model to judge the key bacterial communities and related&#xD;
      functional pathways related to aging.Based on the analysis results, the probiotics with the&#xD;
      potential to alleviate aging were selected for intervention evaluation of aging population.&#xD;
      This topic aims to explore the change process of intestinal flora structure and composition&#xD;
      related to aging process.Identify the key intestinal bacteria genera/species/strains&#xD;
      associated with aging, and target the pathway and metabolic characteristic spectrum of the&#xD;
      key bacterial communities associated with aging;And select and breed specific intestinal&#xD;
      bacterial strains related to aging.The aim is to reduce the age-related metabolic&#xD;
      abnormalities and chronic inflammation, reduce medical treatment, rationally allocate medical&#xD;
      resources, reduce medical costs and improve the quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One group served as a control group, while the other three groups are treated with different strains of bifidobacterium longum</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant ,care provider,investigator and outcomes Assessor are all blind.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Points of probiotics intervention in aging population</measure>
    <time_frame>one year</time_frame>
    <description>The score of Frail scale 0 points is defined as normal.And 1 to 3 points is defined as the early age of debility.Three points or more is defined as debility.The score is lower than before, meaning probiotic intervention can alleviate debility.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Debility</condition>
  <arm_group>
    <arm_group_label>the placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo made of starch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacterium longum group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium longum 274</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacterium longum group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium longum 4-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacterium longum group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium longum gs</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium longum</intervention_name>
    <description>types of intestinal flora</description>
    <arm_group_label>Bifidobacterium longum group 1</arm_group_label>
    <arm_group_label>Bifidobacterium longum group 2</arm_group_label>
    <arm_group_label>Bifidobacterium longum group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>A placebo made of starch</intervention_name>
    <description>placebo</description>
    <arm_group_label>the placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Over 65 years old&#xD;
&#xD;
          2. Frail scale score above 3 points&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe impairment of liver and kidney function&#xD;
&#xD;
          2. The tumor is advanced and life expectancy is less than 2 years&#xD;
&#xD;
          3. Severe cognitive impairment and inability to cooperate&#xD;
&#xD;
          4. Unable to give informed consent&#xD;
&#xD;
          5. Have participated in other study before&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kan Hong, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Wuxi People's hospitial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kan Hong, doctor</last_name>
    <phone>13358119885</phone>
    <email>2898456291@qq.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intestinal flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

